Long-term outcomes of mechanical versus biological valve prosthesis in native mitral valve infective endocarditis

Markus Malmberg, Vesa Anttila, Päivi Rautava, Jarmo Gunn and Ville Kyötiö

Introduction

Patients with native valve infective endocarditis (IE) are at an increased risk of mortality and morbidity, even with current treatment options [1–3]. Although aggressive antimicrobial therapy is the cornerstone of treatment for these patients, up to 50% of these patients undergo surgical intervention [1,4,5]. In native mitral valve endocarditis, surgical correction often requires the replacement of the infected valve (mitral valve replacement, MVR) [6]. Deciding whether MVR should be performed with a mechanical or biological valve prosthesis can be difficult, despite current guidelines and recommendations [4,5,7]. There is limited data on the long-term outcomes of choosing mechanical or biological valve prostheses. Therefore, we aimed to investigate the long-term outcomes of MVR in patients with native mitral valve endocarditis.

Methods

Study design and population

All native valve IE patients aged 16–70 years who had been treated with first-time MVR surgery between January 1, 2004, and December 31, 2017, in Finland (n = 151) were retrospectively identified from the Care Register for Healthcare in Finland (CRHF). Surgical IE treatments performed in six hospitals (five university hospitals and one central hospital) were included in the present study. Patients with histories of prior cardiac surgery (n = 11) or missing mortality data (n = 1) were excluded. The outcomes were all-cause mortality (primary outcome), ischemic stroke, major bleeding, and mitral valve reoperation. These outcomes are described in greater detail in the Supplement. Perioperative ischemic stroke and bleeding events were excluded. The ICD-10 diagnostic codes I33, I38, and I39 were used to identify primary (85% of all patients),
secondary (8%), and tertiary (7%) discharge diagnoses of IE upon surgical admission. Mortality data were obtained from the nationwide cause-of-death registry held by Statistics Finland. Comorbidities were identified in the CRHF admission records and the Finnish Cancer Registry from the beginning of the study to the end of the index admission period, as described previously [8]. The follow-up period ended on December 31, 2018. The registries used in this study are mandated by law in Finland and include full coverage of all hospital admissions, major surgical procedures, and deaths in the Finnish population. This study was approved by the National Institute for Health and Welfare of Finland (permission no. THL/2245/5.05.00/2019) and Statistics Finland (TK-53-484-20). This was a retrospective register study; thus, informed consent was not required, and the participants were not contacted. The legal basis for processing personal data was public interest and scientific research; see EU General Data Protection Regulation 2016/679 (GDPR), Articles 6(1)(e) and 9(2)(j), and Data Protection Act Sections 4 and 6.

**Statistical analysis**

Differences between the study groups were examined with Fisher’s exact tests or t-tests, as appropriate. The outcomes were studied using the Kaplan–Meier method and Cox regression. The multivariable Cox models included age and covariables associated with the outcome at regression. The multivariable Cox models included age and covariables associated with the outcome at regression. The multivariable Cox models included age and covariables associated with the outcome at regression. The multivariable Cox models included age and covariables associated with the outcome at regression. The multivariable Cox models included age and covariables associated with the outcome at regression. The multivariable Cox models included age and covariables associated with the outcome at regression. The multivariable Cox models included age and covariables associated with the outcome at regression.

**Results**

A total of 139 native mitral valves IE patients treated with MVR were included in this study. Of these patients, 63% (\( n = 88 \)) received mechanical valve prosthesis and 37% (\( n = 51 \)) received biological prosthesis. The mean age of all the included patients was 51 (SD = 13.9) years, 74% of the patients were men, and there were no age or gender differences between the study groups (Table 1). Patients with

---

Table 1. Features of native-valve infective endocarditis patients aged 16–70 years treated with mitral valve replacement surgery using mechanical or biological valve prosthesis.

| Variable                     | All patients \( n = 139 \) | Mechanical prosthesis \( n = 88 \) | Biological prosthesis \( n = 51 \) | \( P \)-value* |
|------------------------------|-----------------------------|-------------------------------------|------------------------------------|--------------|
| Age, years (SD)              | 50.7 (13.9)                 | 50.2 (12.0)                         | 51.5 (16.8)                        | 0.63         |
| Men                          | 103 (74.1%)                 | 70 (79.6%)                          | 33 (64.7%)                         | 0.03         |
| Co-morbidities               |                             |                                     |                                    |              |
| Alcohol abuse                | 18 (13.0%)                  | 11 (12.5%)                          | 7 (13.7%)                          | 0.20         |
| Anemia (history of)          | 5 (3.6%)                    | 4 (4.6%)                            | 1 (2.0%)                           | 0.30         |
| Atrial fibrillation          | 13 (9.4%)                   | 8 (9.1%)                            | 5 (9.8%)                           | 0.23         |
| Cerebrovascular disease      | 25 (18.0%)                  | 12 (13.6%)                          | 13 (25.5%)                         | 0.04         |
| Chronic pulmonary disease    | 9 (6.5%)                    | 3 (3.4%)                            | 6 (11.8%)                          | 0.05         |
| Coagulopathy                 | 7 (5.0%)                    | 4 (4.6%)                            | 3 (5.9%)                           | 0.29         |
| Dementia                     | 2 (1.4%)                    | 0 (0.0%)                            | 2 (3.9%)                           | 0.13         |
| Diabetes                     | 14 (10.1%)                  | 6 (6.8%)                            | 8 (15.7%)                          | 0.06         |
| Drug abuse                   | 19 (13.7%)                  | 8 (9.1%)                            | 11 (21.6%)                         | 0.03         |
| Heart failure                | 14 (10.1%)                  | 8 (9.1%)                            | 6 (11.8%)                          | 0.20         |
| Hypertension                 | 28 (20.1%)                  | 17 (19.3%)                          | 11 (21.6%)                         | 0.16         |
| Liver disease                | 18 (13.0%)                  | 6 (6.8%)                            | 12 (23.5%)                         | 0.01         |
| Malignancy (history of)      | 9 (6.5%)                    | 4 (4.6%)                            | 5 (9.8%)                           | 0.13         |
| Periperal vascular disease   | 3 (2.2%)                    | 2 (2.3%)                            | 1 (2.0%)                           | 0.45         |
| Prior myocardial infarction  | 4 (2.9%)                    | 1 (1.1%)                            | 3 (5.9%)                           | 0.12         |
| Psychotic disorder           | 5 (3.6%)                    | 3 (3.4%)                            | 2 (3.9%)                           | 0.35         |
| Systemic rheumatic disease   | 6 (4.3%)                    | 6 (6.8%)                            | 0 (0.0%)                           | 0.06         |
| Renal failure                | 6 (4.3%)                    | 4 (4.6%)                            | 2 (3.9%)                           | 0.33         |
| Concomitant CABG             | 12 (9.4%)                   | 4 (4.6%)                            | 9 (17.7%)                          | 0.01         |
| Extended surgery             | 38 (27.3%)                  | 22 (25.0%)                          | 16 (31.4%)                         | 0.11         |
| Aorta                        | 2 (1.4%)                    | 2 (2.3%)                            | 0 (0.0%)                           | 0.40         |
| Aortic valve                 | 32 (23.0%)                  | 20 (22.7%)                          | 12 (23.5%)                         | 0.16         |
| Tricuspid valve              | 5 (3.6%)                    | 1 (1.1%)                            | 4 (7.8%)                           | 0.06         |
| Pulmonary valve              | 0 (0.0%)                    | 0 (0.0%)                            | 0 (0.0%)                           |              |
| Emergency or urgent surgery  | 75 (54.0%)                  | 42 (56.0%)                          | 33 (64.7%)                         | 0.02         |

SD: Standard deviation; CABG: coronary artery bypass grafting surgery.

*Comparing prosthetic valve types.
known histories of drug abuse were less frequently treated with a mechanical prosthesis (9% vs. 22% of all operated patients, \( p = 0.03 \)). Cerebrovascular disease and liver disease were more frequent in the biological prosthesis group (Table 1). Surgery for IE was extended beyond the mitral valve in 27% of the patients (ascending aorta or aortic root in 1%, aortic valve in 23%, and tricuspid valve in 4%), with no significant differences between the study groups (Table 1).

**Mortality**

There was a total of 48 deaths (25 in the mechanical valve group) during the 12-year follow-up period. The cumulative all-cause mortality rates of all the IE patients were 8.6% at 30 days, 15% at one year, 23% at five years, and 48% at 12 years after MVR (Figure 1). The 12-year mortality rate was lower in patients treated with a mechanical prosthesis (36%) than in patients treated with a biological prosthesis (74%; adj. HR 0.40; CI: 0.17–0.91; \( p = 0.03 \)). The E-value was 4.50 (CI: 1.43–11.14). The association between the mechanical valve and decreased mortality was not modified by known drug abuse history (interaction \( p = 0.51 \)). The short-term mortality rates at 30 days were 8% in the mechanical valve group and 10% in the biological valve group (adj. \( p = 0.63 \)). The one-year mortality rates were 14% for mechanical prostheses and 18% for biological prostheses (adj. \( p = 0.75 \); Table 2). The underlying cause of death was an infection in 35.4% of the deceased patients (Supplement Table 3).

**Ischemic stroke**

At follow-up, the ischemic stroke had occurred in 20 patients (\( n = 12 \) in the mechanical valve group). The overall cumulative stroke rates after MVR were 10% at one year,
15% at five years, and 22% at 12 years. Of the IE patients who were treated with mechanical mitral valve prosthesis, 8% had experienced strokes one year after primary MVR (Figure 2). The one-year ischemic stroke rate was 13% among patients with a biological prosthesis (Table 2). At 12 years, the cumulative stroke rates were 19% in patients with a mechanical prosthesis and 34% in patients with a biological prosthesis (adj. HR 1.44; CI: 0.48–4.38; \( p = 0.52 \)). This association was not modified by drug abuse history (interaction \( p = 0.13 \)). The fatal ischemic stroke rates within the 12-year follow-up period were 1% in the mechanical valve group and 5% in the biological valve group (adj. \( p = 0.76 \)).

**Major bleeding**

The major bleeding event occurred in 18 patients (\( n = 14 \) in the mechanical valve group) during the follow-up. The cumulative major bleeding rates of all the operated IE patients were 6% at one year, 11% at five years, and 26% at 12 years after the MVR operation (Figure 3). The major
bleeding rates at one year were 5% in the mechanical valve group and 7% in the biological valve group (Table 2). The long-term major bleeding rates were 30% for patients who received mechanical valves and 13% for patients who received biological valves (adj. HR 1.84; CI: 0.59–5.67; p = 0.29). Drug abuse history did not modify these results (interaction p = 0.78). Of the 18 first-time major bleeding events during the follow-up period, 22% were intracranial, 22% were gastrointestinal, and 51% were located elsewhere, with no differences in bleeding site distribution between the study groups (p = 0.16). Fatal bleeding occurred in 2% of the patients with biological prosthesis and in none of the patients with a mechanical prosthesis (adj. p = 0.37).

**Mitral valve reoperation**

Mitral valve reoperation had been performed on 4% of all IE patients at one year and 13% of the patients (n = 11) at 12 years after primary MVR. The reoperation rates were 5% in the mechanical valve group and 2% in the biological valve group one year after the primary operation. At the end of the 12-year follow-up period, the reoperation rates were 13% for mechanical prostheses and 12% for biological prostheses (adj. p = 0.50). These results were not modified by drug abuse history (interaction p = 0.58). The indication for reoperation was prosthetic valve infection in 57.1% of the mechanical valve group and 75.0% of the biological valve group (p = 0.42); other indications for reoperation included prosthetic valve deterioration, malfunction, and insufficiency.

**Discussion**

This retrospective, nationwide, population-based cohort study found that in patients who underwent mitral valve replacement for native valve IE, biological valves were associated with increased long-term mortality. Deciding between mechanical and biological valve prostheses for patients requiring MVR can be challenging. According to current guidelines, a mechanical mitral valve prosthesis should be considered for a patient under 65 years of age if there is no contraindication to long-term anticoagulation, taking into account the patient’s medical history and personal preference [7,10]. However, there are no specific guidelines to support a decision when selecting a prosthesis type for surgical IE treatment; rather, this judgement is made individually according to general guidelines and the patient’s overall medical status and lifestyle [4,5,7,10]. In experienced hands, mitral valve repair with good long-term results can be feasible in cases of native mitral valve IE; however, IE patients often require infected valve replacement [6,11].

A recent meta-analysis of over 20,000 patients by Yanagawa et al. showed that mechanical mitral valve prostheses were associated with lower long-term mortality in patients under 70 years of age compared to bioprostheses [12]. Additionally, a propensity score-matched analysis by Hu et al. showed lower long-term mortality after MVR with mechanical prostheses compared to bioprostheses in IE patients aged 50–69 years [13]. On the other hand, a retrospective study by Toyoda et al. indicated no significant difference in the rates of IE recurrence between mechanical and biological valve prostheses 12 years after MVR [14]. Instead, a recent meta-analysis of more than 40,000 patients indicated that a higher rate of recurrence was associated with left-sided IE with bioprostheses in both the aortic and mitral valves [15]. The present results are in line with these findings, as they do not encourage the systematic use of bioprostheses in the surgical treatment of native mitral valve IE.

The present data indicated that patients with a known history of drug abuse were more frequently treated with biological valve prosthesis. Although drug abuse is associated with higher mortality [16], known drug abuse did not significantly modify the association between survival and valve type in the interaction analysis. However, there was no long-term difference in mitral valve-related reoperation rates between the study groups; this may partly explain the survival difference between patients with different valve types.

Although the numbers of ischemic strokes and major bleeding events that occurred during the long-term follow-up period were remarkable, no significant differences in these were found between the study groups. Recent reports have indicated that patients with IE are at an increased risk of both ischemic stroke and bleeding events [17–19]. Although no medication usage data were available for the present study, the results indicated that the oral anticoagulant required for a mechanical valve prosthesis does not necessarily provide sufficient protection from ischemic stroke. On the other hand, oral anticoagulant use with a mechanical valve did not appear to significantly increase the risk of major bleeding compared to the biological valve group during the follow-up period. It remains to be determined whether this finding would persist with a longer follow-up period.

This study had several limitations. The registries used for data collection are considered reliable; however, sources of bias still might have been present [20]. Coding and reporting errors could have been made, and the diagnoses were made by the treating clinicians. A previous validation study showed that the IE diagnoses in the CRHF registry have 96.8% specificity for the Duke criteria [2]. Interpretation of the present results could have been limited by the retrospective nature of the study, and unrecognized residual confounders might have had an impact on the results. The retrospective design of this register study did not allow access to more detailed in-hospital or operative data (e.g., regarding left ventricle ejection fraction, medical therapy, microbiology, or the EuroSCORE). Non-recognized residual confounders are possible. The observed HR of 0.40 for all-cause mortality could be explained away by unmeasured confounders associated with both the prosthetic valve type and death by a risk ratio of 5.0-fold each, above and beyond the measured confounders; however, a weaker confounding could not do so [9]. Despite the nationwide design and the 14-year catchment period, the rarity of the studied condition
resulted in a relatively small number of included patients and thus limited the power of the study.

In conclusion, the findings of this study suggest that patients with native mitral valve IE undergoing MVR have better long-term survival with mechanical valve prosthesis than with bioprosthesis. The results do not support the routine choice of biological mitral valve prostheses for the surgical treatment of mitral valve IE.

**Disclosure statement**

Markus Malmberg has received travel grants and congress sponsorship (Abbott, Boston Lifesciences, Medtronic). Vesa Anttila has received scientific consultancy fees (AstraZeneca), travel grants, and congress sponsorships (Abbott, AtriCure, Medtronic). Päivi Rautava has received speaker fees (Pharmaceutical Information Centre Ltd.). Jarmo Gunn has received an unrestricted research grant (Viifor Pharma). Ville Kytö has received scientific consultancy fees (AstraZeneca), speaker fees (Bayer, Boehringer-Ingelheim, Roche), travel grants, and congress sponsorship (AstraZeneca, Boehringer-Ingelheim, Bayer, Pfizer).

**Funding**

This work was supported by grant funding from the Paulo Foundation, the Finnish Foundation for Cardiovascular Research, and the Finnish Cultural Foundation as well as governmental VTR funding. These funding sources did not have any involvement in the study design; in the collection, analysis, and interpretation of the data; in the writing of the report; or in the decision to submit the article for publication.

**Data availability statement**

The data and study materials will be made available to those who fulfill requirements of applicable Finnish laws and regulations for purposes of reproducing the results or replicating the procedure (from the corresponding author).

**References**

[1] Cahill TJ, Prendergast BD. Infective endocarditis. Lancet. 2016;387(10021):132–893.

[2] Ahtela E, Oksi J, Porela P, et al. Trends in occurrence and 30-day mortality of infective endocarditis in adults: population-based registry study in Finland. BMJ Open. 2019;9(4):e026811.

[3] Habib G, Erba PA, Iung B, et al. Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European Infective Endocarditis) registry: a prospective cohort study. Eur Heart J. 2019;40(39):3222–3232.

[4] Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM), Eur Heart J. 2015;36(44):3075–3128.

[5] Pettersson GB, Coselli JS, Pettersson GB, et al. 2016 The American Association for Thoracic Surgery (AATS) consensus guidelines: surgical treatment of infective endocarditis: executive summary. J Thorac Cardiovasc Surg. 2017;153(6):1241–1258.e29.

[6] Toyoda N, Itagaki S, Egorova NN, et al. Real-world outcomes of surgery for native mitral valve endocarditis. J Thorac Cardiovasc Surg. 2017;154(6):1906–1912.

[7] Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739–2791.

[8] Malmberg M, Gunn J, Rautava P, et al. Outcome of acute myocardial infarction versus stable coronary artery disease patients treated with coronary bypass surgery. Ann Med. 2021;53(1):70–77.

[9] VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268–274.

[10] Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135(25):e1159–e1195.

[11] David TE, Gaerva G, Feindel CM, et al. Surgical treatment of active infective endocarditis: a continued challenge. J Thorac Cardiovasc Surg. 2007;133(1):144–149.

[12] Yanagawa B, Lee J, Ouzounian M, et al. on behalf of the Canadian Cardiovascular Surgery meta-analysis working group. Mitral valve prosthesis choice in patients <70 years: a systemic review and meta-analysis of 2019 patients. J Card Surg. 2020;35:818–825.

[13] Hu X, Jiang W, Xie M, et al. Bioprosthetic vs mechanical mitral valve replacement for infective endocarditis in patients aged 50 to 69 years. Clin Cardiol. 2020;43(10):1093–1099.

[14] Toyoda N, Itagaki S, Tannous H, et al. Bioprosthetic versus mechanical valve replacement for infective endocarditis: focus on recurrence rates. Ann Thorac Surg. 2018;106(1):99–106.

[15] Anantha-Narayanan M, Reddy YNV, Sundaram V, et al. Endocarditis risk with bioprosthetic and mechanical valves: systematic review and meta-analysis. Heart. 2020;106(18):1413–1419.

[16] Ahtela E, Oksi J, Sipilä J, et al. Occurrence of fatal infective endocarditis: population-based study in Finland. BMC Infect Dis. 2019;19(1):987.

[17] Kytöo V, Ahtela E, Sipilä J, et al. Mechanical versus biological valve prosthesis for surgical aortic valve replacement in patients with infective endocarditis. Interact Cardiovasc Thorac Surg. 2019;29(3):386–392.

[18] Klein CF, Gertz S, Wohlfahrt J, et al. Increased risk of ischemic stroke after treatment of infective endocarditis: a Danish, nationwide, propensity score-matched cohort study. Clin Infect Dis. 2020;70:1186–1192.

[19] Malmberg M, Ahtela E, Sipilä JOT, et al. Surgical aortic valve replacement and infective endocarditis. Eur J Clin Invest. 2020;16:e13476.

[20] Sund R. Quality of the Finnish hospital discharge register: a systematic review. Scand J Public Health. 2012;40(6):505–515.